Coagulatory Defects in Type-1 and Type-2 Diabetes

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2020 Jan 1

PMID 31888259

Citations 34

Authors

Amelie I S Sobczak

Alan J Stewart

Affiliations

Soon will be listed here.

Abstract

Diabetes (both type-1 and type-2) affects millions of individuals worldwide. A major cause of death for individuals with diabetes is cardiovascular diseases, in part since both types of diabetes lead to physiological changes that affect haemostasis. Those changes include altered concentrations of coagulatory proteins, hyper-activation of platelets, changes in metal ion homeostasis, alterations in lipid metabolism (leading to lipotoxicity in the heart and atherosclerosis), the presence of pro-coagulatory microparticles and endothelial dysfunction. In this review, we explore the different mechanisms by which diabetes leads to an increased risk of developing coagulatory disorders and how this differs between type-1 and type-2 diabetes.

Citing Articles

Evaluating the Therapeutic Potential of Exercise in Hypoxia and Low-Carbohydrate, High-Fat Diet in Managing Hypertension in Elderly Type 2 Diabetes Patients: A Novel Intervention Approach.

Kindlovits R, Sousa A, Viana J, Milheiro J, Oliveira B, Marques F Nutrients. 2025; 17(3).

PMID: 39940380 PMC: 11819692. DOI: 10.3390/nu17030522.

The role of activated partial thrombin time in mediating the impact of poorly glycemic control on diabetic peripheral neuropathy in patients with type 2 diabetes mellitus.

Zhang H, Chen M, Sun L, Zhu W, Niu T, Fareeduddin Mohammmed Farooqui H Front Endocrinol (Lausanne). 2025; 16:1501323.

PMID: 39917541 PMC: 11798803. DOI: 10.3389/fendo.2025.1501323.

Emerging Role of Natriuretic Peptides in Diabetes Care: A Brief Review of Pertinent Recent Literature.

Tiwari D, Aw T Diagnostics (Basel). 2024; 14(19).

PMID: 39410655 PMC: 11476269. DOI: 10.3390/diagnostics14192251.

Response of Circulating Free Cellular DNA to Repeated Exercise in Men with Type 1 Diabetes Mellitus.

Walczak K, Grzybowska-Adamowicz J, Stawski R, Brzezinska O, Zmyslowska A, Nowak D J Clin Med. 2024; 13(19).

PMID: 39407919 PMC: 11477321. DOI: 10.3390/jcm13195859.

Effects of subcutaneous vs. oral nanoparticle-mediated insulin delivery on hemostasis disorders in type 1 diabetes: A rat model study.

Kaddour N, Benyettou F, Moulai K, Mebarki A, Allal-Taouli K, Ghemrawi R Heliyon. 2024; 10(9):e30450.

PMID: 38711655 PMC: 11070859. DOI: 10.1016/j.heliyon.2024.e30450.

References

Pieters M, Van Zyl D, Rheeder P, Jerling J, Loots D, van der Westhuizen F . Glycation of fibrinogen in uncontrolled diabetic patients and the effects of glycaemic control on fibrinogen glycation. Thromb Res. 2006; 120(3):439-46. DOI: 10.1016/j.thromres.2006.10.016. View

Cefalu W, Schneider D, Carlson H, Migdal P, Gan Lim L, Izon M . Effect of combination glipizide GITS/metformin on fibrinolytic and metabolic parameters in poorly controlled type 2 diabetic subjects. Diabetes Care. 2002; 25(12):2123-8. DOI: 10.2337/diacare.25.12.2123. View

Morel O, Jesel L, Abbas M, Morel N . Prothrombotic changes in diabetes mellitus. Semin Thromb Hemost. 2013; 39(5):477-88. DOI: 10.1055/s-0033-1343888. View

Ali A, Boutjdir M, Aromolaran A . Cardiolipotoxicity, Inflammation, and Arrhythmias: Role for Interleukin-6 Molecular Mechanisms. Front Physiol. 2019; 9:1866. PMC: 6330352. DOI: 10.3389/fphys.2018.01866. View

Khera A, Demler O, Adelman S, Collins H, Glynn R, Ridker P . Cholesterol Efflux Capacity, High-Density Lipoprotein Particle Number, and Incident Cardiovascular Events: An Analysis From the JUPITER Trial (Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin). Circulation. 2017; 135(25):2494-2504. PMC: 5490983. DOI: 10.1161/CIRCULATIONAHA.116.025678. View

Gupta A, Verma A, Kailashiya J, Singh S, Kumar N . Sitagliptin: anti-platelet effect in diabetes and healthy volunteers. Platelets. 2012; 23(8):565-70. DOI: 10.3109/09537104.2012.721907. View

Khunti K, Chatterjee S, Gerstein H, Zoungas S, Davies M . Do sulphonylureas still have a place in clinical practice?. Lancet Diabetes Endocrinol. 2018; 6(10):821-832. DOI: 10.1016/S2213-8587(18)30025-1. View

Cucuianu M, Coca M . Thrombotic tendency in diabetes mellitus. Revisiting and revising a study initiated 30 years ago. Rom J Intern Med. 2013; 50(2):107-15. View

El-Hagracy R, Kamal G, Sabry I, Saad A, Abou El Ezz N, Nasr H . Tissue Factor, Tissue Factor Pathway Inhibitor and Factor VII Activity in Cardiovascular Complicated Type 2 Diabetes Mellitus. Oman Med J. 2011; 25(3):173-8. PMC: 3191644. DOI: 10.5001/omj.2010.52. View

10.

Lamanna C, Monami M, Marchionni N, Mannucci E . Effect of metformin on cardiovascular events and mortality: a meta-analysis of randomized clinical trials. Diabetes Obes Metab. 2011; 13(3):221-8. DOI: 10.1111/j.1463-1326.2010.01349.x. View

11.

Walmsley D, Hampton K, Grant P . Contrasting fibrinolytic responses in type 1 (insulin-dependent) and type 2 (non-insulin-dependent) diabetes. Diabet Med. 1991; 8(10):954-9. DOI: 10.1111/j.1464-5491.1991.tb01536.x. View

12.

Peeters S, Engelen L, Buijs J, Jorsal A, Parving H, Tarnow L . Plasma matrix metalloproteinases are associated with incident cardiovascular disease and all-cause mortality in patients with type 1 diabetes: a 12-year follow-up study. Cardiovasc Diabetol. 2017; 16(1):55. PMC: 5405549. DOI: 10.1186/s12933-017-0539-1. View

13.

Tanka-Salamon A, Komorowicz E, Szabo L, Tenekedjiev K, Kolev K . Free Fatty Acids Modulate Thrombin Mediated Fibrin Generation Resulting in Less Stable Clots. PLoS One. 2016; 11(12):e0167806. PMC: 5152833. DOI: 10.1371/journal.pone.0167806. View

14.

Peeters S, Engelen L, Buijs J, Chaturvedi N, Fuller J, Jorsal A . Circulating matrix metalloproteinases are associated with arterial stiffness in patients with type 1 diabetes: pooled analysis of three cohort studies. Cardiovasc Diabetol. 2017; 16(1):139. PMC: 5657128. DOI: 10.1186/s12933-017-0620-9. View

15.

Aroor A, Manrique-Acevedo C, Demarco V . The role of dipeptidylpeptidase-4 inhibitors in management of cardiovascular disease in diabetes; focus on linagliptin. Cardiovasc Diabetol. 2018; 17(1):59. PMC: 5907287. DOI: 10.1186/s12933-018-0704-1. View

16.

Qi Q, Meigs J, Rexrode K, Hu F, Qi L . Diabetes genetic predisposition score and cardiovascular complications among patients with type 2 diabetes. Diabetes Care. 2012; 36(3):737-9. PMC: 3579364. DOI: 10.2337/dc12-0852. View

17.

Reverter J, Reverter J, Tassies D, Rius F, Monteagudo J, Rubies-Prat J . Thrombomodulin and induced tissue factor expression on monocytes as markers of diabetic microangiopathy: a prospective study on hemostasis and lipoproteins in insulin-dependent diabetes mellitus. Am J Hematol. 1997; 56(2):93-9. DOI: 10.1002/(sici)1096-8652(199710)56:2<93::aid-ajh4>3.0.co;2-w. View

18.

Barillari G, Fabbro E, Pasca S, Bigotto E . Coagulation and oxidative stress plasmatic levels in a type 2 diabetes population. Blood Coagul Fibrinolysis. 2009; 20(4):290-6. DOI: 10.1097/MBC.0b013e328329e49b. View

19.

Rivas Rios J, Franchi F, Rollini F, Angiolillo D . Diabetes and antiplatelet therapy: from bench to bedside. Cardiovasc Diagn Ther. 2018; 8(5):594-609. PMC: 6232350. DOI: 10.21037/cdt.2018.05.09. View

20.

Rao A, Chouhan V, Chen X, Sun L, Boden G . Activation of the tissue factor pathway of blood coagulation during prolonged hyperglycemia in young healthy men. Diabetes. 1999; 48(5):1156-61. DOI: 10.2337/diabetes.48.5.1156. View